Nova Mentis Files Genetic Neuroinflammatory Disease Patent
Messenger RNA Diagnostic/Treatment Paradigm Vancouver, British Columbia – November 9, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has filed a genetic neuroinflammatory disease patent
Read More »
November 9, 2021
Nova Mentis to Present at the Wonderland: Miami Psychedelic Conference
Vancouver, British Columbia – November 4, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will present at Microdose’s Wonderland: Miami psychedelic conference, from November 8-9,
Read More »
November 4, 2021
U.S. FDA Approves Nova Mentis Orphan Drug Application
Psilocybin Fragile X Syndrome Treatment Vancouver, British Columbia – November 2, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that the U.S. FDA has approved the Company’s proprietary psilocybin drug Orphan
Read More »
November 2, 2021
Nova Mentis Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome
Vancouver, British Columbia – October 26, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received orphan drug designation from the European Medicines Agency (EMA) for
Read More »
October 26, 2021
Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders October 19, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, and Mycrodose Therapeutics (“Mycrodose”), a US pharmaceutical company focused
Read More »
October 19, 2021
Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
Vancouver, British Columbia – September 14, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (FDA)
Read More »
September 14, 2021